DRIVIN G ROWTH - Dr. Reddy's

158
schedule to the consolidated balance sheet and profit and loss account
Year ended March 31, 2002 (Rs. thousand)
Formulations Active Generics Diagnostics, Drug discovery Others Eliminations Unallocable Total
pharmaceuticals critical care items
ingredients and and
intermediates biotechnology
External sales 6,168,067 5,213,710 4,526,390 357,878 – 194,075 – – 16,460,120
Inter-segment sales 191,036 479,960 – – – – (670,996) – –
Total sales 6,359,103 5,693,670 4,526,390 357,878 – 194,075 (670,996) 16,460,120
Income from services – – – – – 79,615 – – 79,615
License fees – – – – 343,612 – – – 343,612
Segment revenues 6,359,103 5,693,670 4,526,390 357,878 343,612 273,690 (670,996) – 16,883,347
Interest – – – – – – – 103,786 103,786
Dividend – – – – – – – 35 35
Exchange gain (net) 22,488 62,244 63,923 57 – – – 68,252 216,964
Export benefits 7,111 63,901 – – – – – – 71,012
Miscellaneous income 927 46,441 – – – – – 44,249 91,617
Other unallocable income – – – – – – – 21,339 21,339
Total revenues – – – – – – – – 17,388,100
CONSOLIDATED FINANCIALS | FINANCIALS | ANNUAL REPORT 2001-2002
Segment result 2,186,563 1,077,165 3,794,424 (6,299) (175,592) 3,056 – – 6,879,317
Unallocated expenses – – – – – – – 2,151,524 2,151,524
Finance charges – – – – – – – 114,937 114,937
Profit before taxation – – – – – – – – 4,612,856
Provision for taxation
– Current tax – – – – – – – – 422,092
– Deferred tax expense/ (benefit) – – – – – – – – (356,736)
Profit after taxation – – – – – – – – 4,547,500
Minority Interest-loss – – – – – – – – 31,908
Profit for the year – – – – – – – – 4,579,408